CRISPR Therapeutics reported robust financial results for the fourth quarter of 2025, marking a significant milestone in the commercialization of its flagship gene therapy Casgevy. The treatment generated $116 million in annual revenue while establishing itself in clinical practice with 147 patient initiations—a substantial increase from the prior year that reflects growing physician and patient acceptance of the gene-editing approach.
The expansion in Casgevy adoption signals widening market penetration for the company's in vivo gene-editing therapy. Beyond its lead program, CRISPR is advancing a portfolio of next-generation candidates, including in vivo liver editing programs and RNA-based therapeutic approaches that could extend its addressable market. These pipeline developments position the company to sustain momentum beyond its initial commercial success.
Market sentiment reflected confidence in the company's trajectory, with shares appreciating 8.81% following the earnings announcement. The gains underscore investor optimism regarding both the near-term commercial execution of Casgevy and the longer-term potential of CRISPR's development programs to establish a platform for gene-editing therapeutics across multiple disease indications.